We develop antibody-based therapies targeting IL1RAP

See our pipeline

Our goal is to treat cancer as well as inflammatory and autoimmune diseases

See our clinical program

Strong results provide support for our development programs

See our company presentation

2024-11-21 BioStock Life Science Summit

2024-11-21 BioStock Life Science Summit

CEO Göran Forsberg presents at BioStock Life Science Summit

Watch the presentation here

2024-11-20 Redeye Redeye Autoimmune & inflammatory diseases event

CSO David Liberg presents at Redeye Autoimmune & inflammatory diseases event

Watch the presentation here

2024-11-20 Redeye Redeye Autoimmune & inflammatory diseases event

2024-10-14 Interview with Redeye

2024-10-14 Interview with Redeye

Interview with CEO Göran Forsberg about the latest results from the phase 1 study of CAN10 and the development of nadunolimab in pancreatic cancer.

Watch the interview in Swedish here

Press releases

2024-12-18 Cantargia publishes strong preclinical effects and clinical monotherapy results on nadunolimab in pancreatic cancer in Journal for Immunotherapy of Cancer

2024-12-11 Cantargia and GEICAM present updated phase 1 clinical data and new translational results on nadunolimab treatment in advanced triple negative breast cancer at San Antonio Breast Cancer Symposium

2024-12-04 (R) Cantargia publishes prospectus in connection with rights issue

(R) = Regulatory press releases

Analysis

2024-09-09, Redeye analysis of Cantargia

2024-03-18, Redeye analysis of Cantargia

2024-02-21, Redeye analysis of Cantargia

2023-11-13, Redeye analysis of Cantargia

Current corporate presentation

Download the corporate presentation as PDF

Other presentations

2024-11-21, Video, BioStock Life Science Summit 2024

2024-11-20, Video, Redeye Autoimmune & inflammatory diseases event

2024-10-30, Video, Økonomisk Ugebrev Life Science Investor Conference, Copenhagen (In Swedish)

2024-10-30, Presentation, Økonomisk Ugebrev Life Science Investor Conference, Copenhagen

2024-10-08, Video, LSX Nordic Congress Copenhagen